Results 151 to 160 of about 271,655 (296)

LTB‐TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

British Journal of Haematology, EarlyView.
LTB‐TREAT is a validated international prognostic model that identifies three groups of patients with distinct rates of time to treatment (TTT) in low tumour burden follicular lymphoma. The low‐risk group has a prolonged TTT with WW. The high‐risk group has early progression in whom treatment at diagnosis can be considered. Summary Watchful waiting (WW)
Luani Barge, Lachlan Webb, Anita Pelecanos, Niamh Waters, Ross Salvaris, Sam Lai, Tessa Potezny, Helen Cashman, Caitlyn Nguyen‐Ngo, Denise Lee, Costas K. Yannakou, Nada Hamad, Adrien Chauchet, Sylvain Choquet, Cédric Rossi, Adélie Herbin, Lukshe Kanagaratnam, Cyrielle Rodier, Constantine S. Tam, Abir Bhattacharyya, Chan Y. Cheah, Eliza A. Hawkes, Kirk Morris, Eric Durot, Joshua Tobin, Greg Hapgood   +25 more
wiley   +1 more source

AVD for older patients with classical Hodgkin lymphoma. [PDF]

Blood Adv
Marconi T, Ratnasingam S.
europepmc   +1 more source

Radiotherapy in the Modern Treatment of Hodgkin Lymphoma. [PDF]

Cancer J
Carmicheal J, Enke C.
europepmc   +1 more source

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

British Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace‐Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean‐Marc Schiano De Colella   +15 more
wiley   +1 more source

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

Perinatal and Early-Life Exposures and Risk of Non-Hodgkin Lymphoma. [PDF]

Cancers (Basel)
Cholack GA, Kleinstern G, Robinson DP, Thompson CA, Call TG, Feldman AL, Larson MC, Mwangi R, Ansell SM, Novak AJ, Kay NE, Habermann TM, Cozen W, Slager SL, Cerhan JR.   +14 more
europepmc   +1 more source

[Hodgkin lymphoma and non-Hodgkin lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2013
openaire   +2 more sources

Cutaneous Hodgkin’s lymphoma

South Asian Journal of Cancer, 2017
Asawari Anant Ambekar, Chitralekha S Soman   +1 more
openaire   +3 more sources

How Hot Is Too Hot? Fever Thresholds for Initiating Antibiotics in Children With Haematological Malignancies

Acta Paediatrica, EarlyView.
C. S. V. Henriksen, U. Nygaard, G. Petersen, J. Brok, L. L. Hjalgrim, N. V. Vissing, M. B. Mønster   +6 more
wiley   +1 more source

Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests

British Journal of Haematology, EarlyView.
Summary Haematological malignancies are rare in primary care and are hard to predict. Existing prediction models often require a specific working diagnosis and are based on extensive clinical information, access to which may be limited at initial work‐up in primary care.
Mathilde Egelund Christensen, Michael Charles Sachs, William Grant Dunn, Gustav Jonzon, Margit Kriegbaum, Bent Struer Lind, Jan Samuelsson, Kirsten Groenbaek, George Vassiliou, Christen Lykkegaard Andersen   +9 more
wiley   +1 more source